Evidence map›Paper›PMID 24872700›Full record

ArticleInternational journal of nanomedicine2014

Enhanced MIN-6 beta cell survival and function on a nitric oxide-releasing peptide amphiphile nanomatrix.

Dong-Jin Lim, Adinarayana Andukuri, Jeremy B Vines, Shibli M Rahman, Patrick Tj Hwang, Jeonga Kim, Anath Shalev, John A Corbett, Ho-Wook Jun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dong-Jin LimDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
Adinarayana AndukuriDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
Jeremy B VinesDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA ; Nutech Medical Inc, Division of Endocrinology, Diabetes and Metabolism, Birmingham, AL, USA.
Shibli M RahmanDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
Patrick Tj HwangDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
Jeonga KimDepartment of Medicine, Division of Endocrinology, Diabetes and Metabolism, Birmingham, AL, USA.
Anath ShalevDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA ; Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL, USA.
John A CorbettDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Ho-Wook JunDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA ; Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

BIOCHEMICAL MECHANISM OF BETA-CELL DESTRUCTIONR01DK052194 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CORBETT, JOHN A · 1998 to 2025
$8.8M
UAB Diabetes Research and Training CenterP60DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GARVEY, W TIMOTHY · 2008 to 2012
$8.4M
MECHANISMS OF VIRAL INDUCED BETA CELL DAMAGER01AI044458 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CORBETT, JOHN A · 1998 to 2024
$7.5M
Cell therapy for diabetic peripheral neurovascular complicationsDP3DK094346 · NIDDK · EMORY UNIVERSITY · PI CHENG, XIAODONG, YOON, YOUNG-SUP · 2011 to 2011
$6.1M
Prohealing multifunctional endothelium nanomatrix coated stentR01HL125391 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JUN, HO-WOOK · 2015 to 2019
$1.8M
A hybrid nanosack for the enhanced islet engraftment in the omentumR03EB017344 · NIBIB · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JUN, HO-WOOK · 2013 to 2014
$143k
NHLBI NIH HHS R01 HL125391NIAID NIH HHS R01 AI044458NIBIB NIH HHS 1R03EB017344-01NIBIB NIH HHS R03 EB017344NIDDK NIH HHS 1DP3DK094346-01NIDDK NIH HHS DP3 DK094346NIDDK NIH HHS P60 DK079626NIDDK NIH HHS P60DK-079626NIDDK NIH HHS R01 DK052194
6 · The paper itself

Abstract

Innovative biomaterial strategies are required to improve islet cell retention, viability, and functionality, and thereby obtain clinically successful outcomes from pancreatic islet cell transplantation. To address this need, we have developed a peptide amphiphile-based nanomatrix that incorporates multifunctional bioactive cues and sustained release of nitric oxide. The goal of this study was to evaluate the effect of this peptide amphiphile nanomatrix on the viability and functionality of MIN-6 islet cells. Additionally, this study provides insight into the role of nitric oxide in islet cell biology, given that conventional nitric oxide donors are unable to release nitric oxide in a controlled, sustained manner, leading to ambiguous results. It was hypothesized that controlled nitric oxide release in synergy with multifunctional bioactive cues would promote islet cell viability and functionality. Nitric oxide-releasing peptide amphiphile nanomatrices within the range of 16.25 μmol to 130 μmol were used to analyze MIN-6 cell behavior. Both 32.5 μmol and 65 μmol peptide amphiphiles showed improved MIN-6 functionality in response to glucose over a 7-day time period, and the elevated functionality was correlated with both PDX-1 and insulin gene expression. Our results demonstrate that nitric oxide has a beneficial effect on MIN-6 cells in a concentration-dependent manner.

Indexed as

AnimalsCell LineCell ProliferationCell SurvivalGlucoseIslets of LangerhansMiceNanostructuresNitric OxidePeptidesGlucoseNitric OxidePeptidesbeta cellsbiomimeticdiabetesnitric oxidepeptide amphiphile

Identifiers

PMID24872700
PMCPMC4024973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.